食管癌靶向及免疫治疗研究进展  

Research progress in targeted and immunotherapy for esophageal cancer

作　　者：黄镇 晏菲 马燕凌 孙建海 Huang Zhen;Yan Fei;Ma Yanling;Sun Jianhai(Department of Oncology,Third People's Hospital of Hubei Province,Jianghan University,Wuhan 430033,China)

机构地区：[1]江汉大学附属湖北省第三人民医院肿瘤科,武汉430033

出　　处：《国际肿瘤学杂志》2025年第1期53-59,共7页Journal of International Oncology

摘　　要：食管癌的早期诊断率低,大部分患者确诊时已处于中晚期,治疗难度大,生存期短,预后极差。近年来靶向治疗和免疫治疗的不断发展显著改善了食管癌患者的生存率和治疗效果。分析食管癌靶向治疗和免疫治疗的研究进展具有重要意义,可为指导食管癌治疗提供参考。The early diagnosis rate of esophageal cancer is low,and most of the patients are already in the middle or late stage when diagnosed,making treatment difficult,shortening the survival period and resulting in an extremely poor prognosis.In recent years,the continuous development of targeted therapy and immunotherapy has significantly improved the survival rate and therapeutic effect of esophageal cancer patients.Analyzing the research progress of targeted therapy and immunotherapy for esophageal cancer is of great significance and can provide reference for guiding the treatment of esophageal cancer.

关 键 词：食管肿瘤 分子靶向治疗 免疫疗法 治疗结果 

分 类 号：R73[医药卫生—肿瘤]